Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 32, 2002 - Issue 1
213
Views
51
CrossRef citations to date
0
Altmetric
Original Article

CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro

, , &
Pages 1-17 | Received 04 May 2001, Published online: 12 Jul 2010

References

  • AUNGST, B. J., 1999, P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Advances in Drug Delivery Review, 39, 105–116.
  • BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261–270.
  • BIRKETT, D. J., MACKENZIE, P. I., VERONESE, M. E. and MINERS, J. O., 1993, In vitro approaches can predict human drug metabolism. TIPS, 4, 292–294.
  • CHANG, T. K. H., GONZALEZ, F. J. and WAXMAN, D. J., 1994, Evaluation of triacetyloleandomycin, ct-naphthofiavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochrome P450. Archives of Biochemical Biophysics, 311, 437–442.
  • CHIBA, M., HENSLEIGH, M. and LIN, J. L., 1997, Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochemical Pharmacology, 53, 1187–1195.
  • CRAIG, J. C., DUNCAN, I. B., HOCKLEY, D., GRIEF, C., ROBERTS, N. A. and MILLS, J. S., 1991, Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Research, 16, 295–305.
  • DECKER, C. J., LAITINER, L. M., BRIDSON, G. W., RAYBUCK, S. A., TUNG, R. D. and CHATURREDI, P. R., 1998, Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. Journal of Pharmaceutical Science, 87, 803–807.
  • EAGLING, V. A., BACK, D. J. and BARRY, M. G., 1997, Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. British Journal of Clinical Pharmacology, 44, 190–194.
  • EAGLING, V. A., THA, J. T. and BACK, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107–114.
  • FRRZSIMMONS, M. E. and COLLINS, J. M., 1997, Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small intestinal cytochrome P450. Drug Metabolism and Disposition, 25, 256–267.
  • GENTILE, D. M., TOMLINSON, E. S., MAGGS, J. L., PARK, B. K. and BACK, D. J., 1996, Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. Journal of Pharmacology and Experimental Therapeutics, 277, 105–112.
  • GUENGERICH, F. P., Kim, D. H. and IwAsmo, M., 1991, Role of human cytochrome P450 11E1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology, 4, 168–179.
  • HALBERT, J. R., GUENGERICH, F. P., BEND, J. R. and CORREIA, M. A., 1994, Selective inhibitors of cytochromes P450. Toxicology and Applied Pharmacology, 125, 163–175.
  • HOUSTON, J. B., 1994, Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology, 47, 1469–1479.
  • KIM, R. B., FROMM, M. F., WANDEL, C., LEAKE, B., WOOD, A. J. J., RODEN, D. M. and WILKINSON, G. R., 1998, The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Journal of Clinical Investigation, 101, 289–294.
  • KOLARS, J. C., SCHMIEDLIN-REN, P., SCHUETZ, J. D., FANG, C. and WATKINS, P. B., 1992, Identification of rifampicin-inducible P4503A4 in human small bowel enterocytes. Journal of Clinical Investigation, 90, 1871–1878.
  • KUMAR, G. N., RODRIGUES, A. D., BUKO, A. M. and DENISSEN, J. F., 1996, Cytochrome P450 mediated metabolism of the HIV-1 protease inhibitor Ritonavir (ABT-538) in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 23–31.
  • KUNZE, K. L. and TRAGER, W. F., 1993, Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chemical Research in Toxicology, 6, 649–656.
  • LEE, C. G. L., GOTTESMAN, M. M., CARDARELLI, C. O., RAMACHANDRA, M., JEANG, K.-T., AMBUDCAR, S. V., PASTAN, I. and DEY, S., 1998, HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry, 37, 3594–3601.
  • LEWIS, D. V. F., EDDERSHAW, P. J., GLODFARB, P. S. and TARBIT, M. H., 1996, Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica, 26, 1067–1086.
  • LOWN, K. S., GHOSH, M. and WATKINS, P. B., 1998, Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical. Drug Metabolism and Disposition, 26, 185–187.
  • LOWN, K. S., MAYO, R. R., LEICHTMAN, A. B., HSIAO, H., TURGEON, K., SCHMEIDLIN-REN, P., BROWN, M. B., Guo, W., Rossi, S. J. BENET, L. Z. and WATKINS, P. B., 1997, Role of intestinal P-glycoprotein (mdrl) in interpatient variation in the oral bioavailability of cyclosporine. Clinical and Pharmacology and Therapeutics, 62, 248–260.
  • LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein determination with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
  • MERRY, C., BARRY, M. G., MULCAHY, F., HALIFAX, K. L. and BACK, D. J., 1997b, Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS, 11, F117—F120.
  • MERRY, C., BARRY, M. G., MULCAHY, F., RYAN, M., HEAVEY, J., TPA, J. F., GIBBONS, S. E., BRECKENRIDGE, A. M. and BACK, D. J., 1997a, Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV infected patients. AIDS, 11, F29—F33.
  • NOBLE, S. and FAULDS, D., 1996, Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs, 52, 93–112.
  • PERRY, C. M. and NOBLE, S., 1998, Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs, 55, 461–486.
  • PROFIT, L., EAGLING, V. A. and BACK, D. J., 1999, Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS, 13, 1623–1627.
  • PRUEESARITANONT, T., GORHAM, L. M., HOCHMAN, J. H., TIN, L. O. and VYAS, K. P., 1996, Comparative studies of drug metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2-cells. Drug Metabolism and Disposition, 24, 634–642.
  • SESARDIC, D., Booms, A. R., MURRAY, B. P., SEGURA, J., DE LA TORRE, R. and DAVIES, D. S., 1990, Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. British Journal of Clinical Pharmacology, 29, 651–663.
  • STEIMER, J. L., FOTTELER, B., GIESCHKE, R., WILTSHIRE, H. and Buss, N., 1998, Predicting the optimal dose of saquinavir via modelling of dose—exposure and exposure—effect relationships. In M. Danhof and J. L. Steimer (eds), Measurement and Kinetics of In Vivo Drug Effects: Advances in Simultaneous PharmacokineticlPharmacodynamk Modelling (Leiden: Amsterdam Center for Drug Research), pp. 79–86.
  • VON MOLTKE, L. L., GREENBLATT, D. J., GRASSI, J. M., GRANDA, B. W., DUAN, S. X., FOGELMAN, S. M., DAILY, J. P., HARMATZ, J. S. and SHADER, R. I., 1998, Protease inhibitors as inhibitors of human cyto chromes P450: high risk associated with ritonavir. Journal of Clinical Pharmacology, 38, 106–111.
  • WAXMAN, D. J., ÄTTISANO, C., GUENGERICH, F. P. and LAPENSON, D. P., 1988, Human liver microsomal steroid metabolism. Identification of the major microsomal steroid 60 hydroxylase cytochrome P450 enzyme. Archives in Biochemistry and Biophysics, 290, 160–166.
  • WAXMAN, D. J., LAPENSON, D. P., ÄOYAMA, T., GELBOIN, H. V., GONZALEZ, F. J. and KORZEKWA, K., 1991, Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Archives in Biochemistry and Biophysics, 290, 160–166.
  • WILTSHIRE, H. R., PRIOR, K. J., DHESI, J., TRACH, F., SCHLAGETER, M. and SCHöNENBERGER, H., 1998, The synthesis of labelled forms of saquinavir. Journal of Labelled Compounds and Radiopharmacology, 41, 1103–1126.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.